Literature DB >> 15096075

Adherence to conventional and atypical antipsychotics after hospital discharge.

Esperanza Diaz1, Elizabeth Neuse, Michelle C Sullivan, H Rowland Pearsall, Scott W Woods.   

Abstract

BACKGROUND: This prospective study measured adherence to conventional and atypical antipsychotics after hospital discharge in patients with a diagnosis of schizophrenia and schizoaffective disorder. We examined the interaction of several predictors such as gender, severity of illness, attitudes toward medications, side effects, and dose frequency.
METHOD: The sample consisted of consecutive randomized and nonrandomized patients who were discharged from an inpatient unit with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder between December 1995 and July 1999. All patients were taking oral antipsychotics and consented to the use of an electronic adherence monitor at discharge. Medications were prescribed by usual care providers, and medication adherence was followed weekly for 3 months. The outcome measure was the medication adherence rate registered in the electronic monitors.
RESULTS: We found no significant difference in adherence between the combined groups of atypical and conventional antipsychotics. Individual medication analysis found better medication adherence with olanzapine in comparison with risperidone and conventional antipsychotics, but the difference disappeared in the final model controlling for dose frequency. Dose frequency, gender, and akathisia predicted adherence.
CONCLUSIONS: Olanzapine initially appeared to be associated with an adherence advantage over risperidone and conventional antipsychotics, but the apparent advantage may have been due to a usual care dose frequency practice that associated olanzapine more often with once-daily dosing. This study suggests that dose frequency is an important predictor of medication adherence. An important caveat is that these results apply only to short-term adherence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096075     DOI: 10.4088/jcp.v65n0311

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

1.  Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies.

Authors:  Keming Gao; David E Kemp; Zuowei Wang; Stephen J Ganocy; Carla Conroy; Marry Beth Serrano; Martha Sajatovic; Robert L Findling; Joseph R Calabrese
Journal:  Psychopharmacol Bull       Date:  2010

2.  A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.

Authors:  Paul A Nakonezny; Carroll W Hughes; Taryn L Mayes; Kathryn H Sternweis-Yang; Betsy D Kennard; Matthew J Byerly; Graham J Emslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-10       Impact factor: 2.576

Review 3.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 4.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

5.  Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Hiroyoshi Takeuchi; Kensuke Nomura; Akira Tanabe; Koichiro Watanabe; Gohei Yagi; Haruo Kashima
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

6.  Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.

Authors:  Qian Li; Yun Ai Su; Yi Liu; Jing Xu Chen; Yun Long Tan; Fu De Yang; Tian Mei Si
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

7.  The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.

Authors:  Paul A Nakonezny; Matthew J Byerly; Amit Pradhan
Journal:  Psychiatry Res       Date:  2013-03-06       Impact factor: 3.222

8.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

9.  New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

Authors:  Bernhard T Baune
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.